Literature DB >> 16703366

Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy.

Markus Schwaiger1, Christian Peschel.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16703366     DOI： 10.1007/s00259-006-0128-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  37 in total

1.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

2.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Authors:  Norbert Avril; Stefanie Sassen; Barbara Schmalfeldt; Joerg Naehrig; Stephan Rutke; Wolfgang A Weber; Martin Werner; Henner Graeff; Markus Schwaiger; Walther Kuhn
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

Review 3.  Tumor oxygenation status as a prognostic marker.

Authors:  Chandrakala Menon; Douglas L Fraker
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

Review 4.  Her-2/neu as a paradigm of a tumor-specific target for therapy.

Authors:  A Choudhury; R Kiessling
Journal:  Breast Dis       Date:  2004

5.  FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.

Authors:  Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

Review 6.  Monitoring response to treatment in patients utilizing PET.

Authors:  Norbert E Avril; Wolfgang A Weber
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

Review 7.  Imaging hypoxia and angiogenesis in tumors.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

8.  Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Authors:  Robert M Sharkey; Arnold Brenner; Jack Burton; George Hajjar; Stephen P Toder; Abass Alavi; Alexander Matthies; Donald E Tsai; Stephen J Schuster; Edward A Stadtmauer; Myron S Czuczman; Dominick Lamonica; Françoise Kraeber-Bodere; Beatrice Mahe; Jean-François Chatal; André Rogatko; George Mardirrosian; David M Goldenberg
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

9.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

10.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.